As a leading technology provider, Creative Biolabs has established CellRapeutics™ Chimeric Antigen Receptor (CAR) Technology platform. https://www.creative-biolabs.com/car-t/cellrapeutics-chimeric-antigen-receptor-car-technology.htm

1. Surfarray™ Cell
Microarray Technology
Search the Best-in-class CAR-T Cells for
Immunotherapy
www.creative-biolabs.com/car-t/
With unrivaled expertise and experience in the discovery and development of various immunotherapies, Creative
Biolabs independently developed a novel Surfarray™ Cell Microarray Technology to support our clients' cellular
therapy research. We offer Surfarray™ Cell Microarray Technology to best suit your program requirements.
Background
In medical research and drug discovery, it is often highly advantageous or even essential to identify the cell
surface proteins that are targeted by a molecule of interest. Cell microarray technology is a powerful tool for the
discovery of human cell surface and secretory protein targets for various antibodies, proteins, and small
molecules. This method can process thousands of units simultaneously, enabling a wide screening on only a few
slides, which could increase the output significantly. By doing so, a global map of cellular functions can be
generated to further our understanding of both normal biological and disease processes.
Creative Biolabs' unique and highly sensitive Surfarray™ cell microarray technology allows us to provide fast,
accurate, and efficient solutions to our customers around the world:
• Discover novel, high quality, and developable cell therapy targets.
• Detect specific interactions with a high degree of sensitivity.
• Widely covering known plasma membranes and secreted protein subclasses.
• Explore safety liability of lead candidates.

2. Key Applications of Cell Microarray Technology
Cell-based microarrays can be used in various applications. Our case studies focus on providing more details on
receptor identification, targeted deconvolution, and specific screening of biotherapeutics such as CAR-T cells and
antibodies. Our key applications include but are not limited to the followings:
Target Deconvolution
Target deconvolution has traditionally been a well-recognized
bottleneck in phenotypic discovery. Cellular microarray
technology is well suited for target deconvolution. It ranges from
the primary targets of revealing antibodies or small molecule
compounds identified by phenotypic screening to commercially
available drugs. Our microarray technology is widely used for
CAR-T and antibody target deconvolution:
• Discover novel, high-quality, and developable cell therapy targets.
• Receptor molecules are targeted by phenotypic molecules.
(antibodies, scFvs, Fc-fusion proteins, etc.).
• Identification of disease-specific antigens by screening patient sera.
Receptor Identification
Our cell microarrays are optimized for the identification of
physiologically relevant cell surface interactions, which can
vastly increase the chances of finding a ligand's receptor. It
recognizes cell surface receptors and secreted targets of a
wide range of molecules ranging from purified proteins to
more complex ligands such as whole cells:
• Natural soluble proteins and peptides
• Live viruses and virus-like particles (VLPs)

3. • Cell surface derived ligands
• Whole cells expressing the ligand of interest
Off-target Profiling
Toxicity derived from off-target binding to either cell surface or
secreted proteins causes serious concern in drug development.
Our off-target analysis is used to assess off-targets of plasma
membranes and secreted proteins expressed in human cells.
Highlights:
• Has a very low false positive/negative number.
• Can predict/interpret reduced bioavailability due to off-target binding.
• Can inform pre-clinical toxicity model selection and reduce animal
testing.
Off-target profiling
• Monoclonal or bispecific antibodies
• ScFvs, Fabs, or antibody derivatives
• Peptides
• Protein ligands
• Labelled small molecules
CAR-T Cells Specificity Screening
To ensure patient's safety, the risk of triggering an inappropriate
immune response should be minimized, such as unanticipated
off-target binding of the engineered CAR-T cells. Our cell
microarray technology can label and screen entire CAR-T cells
and can be used to evaluate final engineered cells as well as
precursor antibodies/scFv.
There are two methods for targeted screening of CAR-T cells:
• Screening of antigen recognition elements—scFv
• Screening of engineered CAR T cells
Early specific screening can help with the selection of the right
scFv to maximize the chances of producing the most promising
potential CAR T therapy. A more relevant off-target assessment
can then be provided by screening the entire engineered T cells
(or final scFv).

4. Novel Immune Checkpoints Discovery
Identifying new immune checkpoint therapeutic targets provides
important scientific value to our customers. Since many
important immune checkpoint interactions have not been fully
characterized, we use cell microarray technology to identify
immunological checkpoint targets with high specificity.
Contact us for case studies and we'll show you how to use cell
microarray technology to identify immune checkpoint targets
with high specificity.
Creative Biolabs is dedicated to helping our worldwide customers shorten the time in the discovery and
development of CAR-T cell therapy. We utilize proprietary drug design, study data, product candidates, advanced
project life-cycle management, as well as real-time data to ensure the ideal outcomes.
For more detailed information, please feel free to contact us.
Creative Biolabs take the advantages of CAR-T strategy to help researchers accelerate the CAR therapeutic
development and make history in fighting malicious cancers.
References:
1. Freeth J, Soden J. SLAS Discovery. 2020 25 (2) 223-230.
2. Castel D, Pitaval A, et al. Drug Discovery Today. 2006 Jul 11;(13)..
Email: info@creative-biolabs.com

5. Copyright © 2020 Creative Biolabs. All Rights Reserved.